FDA calendar · October 2020 · built from SEC filings

PDUFA dates October 2020: FDA calendar and catalysts.

Updated Snapshot 20261116T222116ZBuilt

0 PDUFA dates fell in October 2020. The FDA calendar also recorded 13 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in October 2020

No PDUFA dates are disclosed for this period as of November 16, 2026.

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

October 2020: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
October 2, 2020Yervoy® (ipilimumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
October 2, 2020Opdivo® (nivolumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
October 2, 2020KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
October 9, 2020Ultomiris (ravulizumab-cwvz)AZNLabel expansion—ApprovedopenFDA Drugs@FDA
October 13, 2020WAKIX® (pitolisant)HRMYFDA approval—ApprovedopenFDA Drugs@FDA
October 14, 2020KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
October 14, 2020Inmazeb (atoltivimab; maftivimab; odesivimab)REGNFDA approval—ApprovedopenFDA Drugs@FDA
October 16, 2020Venclexta (venetoclax)ABBVLabel expansion—ApprovedopenFDA Drugs@FDA
October 19, 2020Arikayce Kit (amikacin sulfate)INSMLabel expansion—ApprovedopenFDA Drugs@FDA
October 22, 2020Veklury (remdesivir)GILDFDA approval—ApprovedopenFDA Drugs@FDA
October 22, 2020Talzenna (talazoparib tosylate)PFELabel expansion—ApprovedopenFDA Drugs@FDA
October 26, 2020Eysuvis (loteprednol etabonate)ALCFDA approval—ApprovedopenFDA Drugs@FDA
October 30, 2020Selzentry (maraviroc)GSKLabel expansion—ApprovedopenFDA Drugs@FDA

October 2020: dated readouts

No events in this view.

Questions

What PDUFA dates are in October 2020?

0 PDUFA dates fell in October 2020. The FDA calendar also recorded 13 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.